We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
+2.68%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$1.39B
AUM Growth
+$197M
Cap. Flow
+$227M
Cap. Flow %
16.33%
Top 10 Hldgs %
54.77%
Holding
74
New
16
Increased
17
Reduced
14
Closed
17

Top Buys

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$61.8M
2
IDYA icon
IDEAYA Biosciences
IDYA
+$41.4M
3
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$39.5M
4
PMVP icon
PMV Pharmaceuticals
PMVP
+$38.1M
5
ARNA
Arena Pharmaceuticals Inc
ARNA
+$30.1M

Top Sells

Rank Stock Value
1
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$31.2M
2
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
+$26.9M
3
VERV
Verve Therapeutics
VERV
+$18.5M
4
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$15.8M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$14.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.99%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LONA
26
LeonaBio Inc
LONA
$69.3M
$17.4M 1.26%
185,581
+44,500
+32% +$4.53M
IPSC icon
27
Century Therapeutics
IPSC
$379M
$16.1M 1.16%
639,095
-350,000
-35% -$9.47M
JNCE
28
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$14.9M 1.07%
+2,000,000
New +$12.4M
PRLD icon
29
Prelude Therapeutics
PRLD
$314M
$12.5M 0.9%
400,000
– –
IOVA icon
30
Iovance Biotherapeutics
IOVA
$2.2B
$12.3M 0.89%
500,000
-625,000
-56% -$14.7M
EWTX icon
31
Edgewise Therapeutics
EWTX
$4.47B
$10.8M 0.78%
681,812
-550,000
-45% -$9.95M
BMEA icon
32
Biomea Fusion
BMEA
$92.5M
$8.41M 0.61%
702,320
-460,000
-40% -$5.85M
ELDN icon
33
Eledon Pharmaceuticals
ELDN
$277M
$8.28M 0.6%
1,339,793
– –
EPIX
34
DELISTED
ESSA Pharma
EPIX
$8M 0.58%
+1,000,000
New +$15.9M
ALT icon
35
Altimmune
ALT
$576M
$7.92M 0.57%
+700,000
New +$8.51M
COGT icon
36
Cogent Biosciences
COGT
$6.94B
$7.78M 0.56%
925,000
-495,500
-35% -$3.8M
BCEL
37
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$7.32M 0.53%
+1,175,000
New +$7.83M
TRML
38
DELISTED
Tourmaline Bio
TRML
$6.89M 0.5%
50,792
– –
RAIN
39
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$6.61M 0.48%
465,331
-315,000
-40% -$5.37M
CGEM icon
40
Cullinan Oncology
CGEM
$1.1B
$6.51M 0.47%
288,458
– –
GHRS icon
41
GH Research
GHRS
$1.91B
$6.44M 0.46%
324,333
-400,000
-55% -$8.14M
JANX icon
42
Janux Therapeutics
JANX
$962M
$4.81M 0.35%
247,122
-300,000
-55% -$8.63M
SYBX
43
DELISTED
Synlogic
SYBX
$4.58M 0.33%
+100,000
New +$4.67M
ALPN
44
DELISTED
Alpine Immune Sciences Inc
ALPN
$4.54M 0.33%
+425,000
New +$3.92M
STTK icon
45
Shattuck Labs
STTK
$710M
$4.08M 0.29%
+200,000
New +$4.28M
IMA
46
ImageneBio Inc
IMA
$63.2M
$3.78M 0.27%
24,988
– –
DAWN
47
DELISTED
Day One Biopharmaceuticals
DAWN
$2.8M 0.2%
52,069
+15,000
+40% +$359K
NUVL
48
DELISTED
Nuvalent
NUVL
$2.73M 0.2%
+134,650
New +$3.91M
SLGC
49
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$2.24M 0.16%
+200,493
New +$2.26M
KNTE
50
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$2.17M 0.16%
94,345
-1,235,257
-93% -$26.9M
1
2
3

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q3 2021 Portfolio in Review

As of Q3 2021, Logos Global Management held 74 positions worth $1.39B, up 17% from $1.19B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Logos Global Management deployed $227M of net new capital in Q3 2021, opening 16 new positions and adding to 17 existing holdings. Its largest new stake was IDEAYA Biosciences: 1,775,000 shares worth $45.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Kinnate Biopharma Inc. Common Stock, an estimated $26.9M trimmed.

  • Logos Global Management's largest Q3 2021 buy was IDEAYA Biosciences: 1,775,000 shares worth $45.2M.
  • Logos Global Management added most to Apellis Pharmaceuticals in Q3 2021, an estimated $61.8M increase.
  • Logos Global Management's biggest Q3 2021 reduction was Kinnate Biopharma Inc. Common Stock, cutting an estimated $26.9M.
  • Logos Global Management fully exited Turning Point Therapeutics, Inc. Common Stock in Q3 2021, selling an estimated $31.2M.
  • Logos Global Management's ten largest holdings make up 55% of its $1.39B portfolio in Q3 2021.
  • Logos Global Management opened 16 new positions and closed 17 in Q3 2021.
  • Logos Global Management's portfolio value rose 17% quarter-over-quarter to $1.39B.

Based on Logos Global Management's 13F filing for Q3 2021, filed 15 Nov 2021.